Sage Therapeutics (NASDAQ:SAGE – Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, October 29th. Analysts expect Sage Therapeutics to post earnings of ($1.53) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.
Sage Therapeutics (NASDAQ:SAGE – Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.02). Sage Therapeutics had a negative return on equity of 55.87% and a negative net margin of 458.30%. The business had revenue of $8.65 million during the quarter, compared to analyst estimates of $8.85 million. During the same quarter last year, the firm earned ($2.68) EPS. Sage Therapeutics’s revenue for the quarter was up 249.8% compared to the same quarter last year. On average, analysts expect Sage Therapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Sage Therapeutics Stock Up 2.9 %
Shares of Sage Therapeutics stock opened at $7.79 on Tuesday. Sage Therapeutics has a twelve month low of $5.84 and a twelve month high of $28.26. The company has a 50-day simple moving average of $7.55 and a two-hundred day simple moving average of $10.35. The stock has a market capitalization of $475.58 million, a price-to-earnings ratio of -1.05 and a beta of 0.91.
Analyst Ratings Changes
Get Our Latest Research Report on SAGE
About Sage Therapeutics
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Featured Stories
- Five stocks we like better than Sage Therapeutics
- The Basics of Support and Resistance
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Where to Find Earnings Call Transcripts
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.